CordenPharma increases xRNA-based capabilities with LNP formulation investment in Italy 06-Jun-2022 By Rachel Arthur CDMO CordenPharma has increased its xRNA capabilities at its sterile injectable facility in Caponago, Italy: with a €10m ($10.7m) investment in new Lipid Nanoparticle (LNP) formulation, development and production areas.